Fulgent Genetics, Inc. (FLGT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$19.73+0.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · FLGT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | 323.9 | 322.7 | 283.5 | 289.2 | 619.0 | 992.6 | 421.7 | 32.5 | 21.4 | 18.7 | 18.3 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 18.7 | 18.3 |
| Cost of Revenues | 208.7 | 191.8 | 176.3 | 184.8 | 252.1 | 215.5 | 89.8 | 0.0 | 0.0 | 8.6 | 6.7 |
| Gross Profit | 115.3 | 130.9 | 107.2 | 104.5 | 366.9 | 777.1 | 331.9 | 18.4 | 10.7 | 10.2 | 11.6 |
| Operating Expenses & Income | |||||||||||
| R&D Expenses | 56.8 | 53.9 | 48.8 | 41.4 | 28.9 | 24.2 | 11.6 | 6.5 | 5.5 | 4.2 | 3.6 |
| Operating Income | (122.3) | (91.1) | (73.9) | (195.5) | 178.5 | 676.0 | 290.2 | (0.4) | (5.1) | (3.5) | 0.9 |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | 0.1 | (0.2) | — | 0.3 | 0.1 | 0.0 | — | — | — | — |
| Interest & Investment Income | 29.9 | 30.9 | 31.3 | 21.6 | 5.6 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | (5.3) | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 29.8 | 21.1 | 22.0 | 21.4 | 5.5 | — | — | — | — | — | — |
| Asset Writedown | — | 9.9 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (92.5) | (70.0) | (52.0) | (174.1) | 184.0 | 677.3 | 291.7 | 0.4 | (4.6) | (3.0) | (4.5) |
| Income Tax Expense | (7.0) | (8.4) | (8.1) | 1.2 | 42.1 | 174.8 | 72.5 | 0.0 | 0.0 | (1.0) | 0.9 |
| Net Income | |||||||||||
| Minority Interest | (1.1) | (1.1) | (1.1) | (7.4) | (1.5) | (1.1) | — | — | — | — | — |
| Net Income | (84.4) | (60.5) | (42.7) | (167.8) | 143.4 | 507.4 | 214.3 | (0.4) | (5.6) | (2.5) | (5.3) |
| Per Share | |||||||||||
| Basic EPS | (3.01) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (3.01) | — | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 11.57 | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 28.0 | 30.8 | 30.2 | 29.8 | 30.1 | 29.4 | 22.7 | 18.7 | 18.0 | — | — |
| Diluted Weighted Avg Shares | 28.0 | 30.8 | 30.2 | 29.8 | 31.0 | 31.0 | 24.1 | 18.7 | 18.0 | — | — |
| Supplemental | |||||||||||
| EBITDA | — | (67.0) | (49.0) | (169.4) | 211.2 | 687.0 | 293.1 | — | — | (1.8) | 2.1 |
| EBIT | (122.3) | (91.1) | (73.9) | (195.5) | 178.5 | 676.0 | 290.2 | (0.4) | (5.1) | (3.5) | 0.9 |
| Effective Tax Rate | 7.6% | — | — | -0.7% | 22.9% | 25.8% | 24.9% | 10.5% | -0.8% | 33.8% | -20.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.